In recent years, along with the increased potential of eEF2K as a drug target in cancer, as well as in cardiovascular and neurodegenerative diseases, a growing attention has been paid to the development of eEF2K inhibitors [30]. The gene discussed is EEF2K; the disease is neurodegenerative disease.